A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo

SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

(2021) Haibin Zhou et al.   ACS Medicinal Chemistry Letters

The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences

(2021) Yasset Perez-Riverol et al.   NUCLEIC ACIDS RESEARCH

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

(2020) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia

(2019) Barbara Maurer et al.   HAEMATOLOGICA

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

(2019) Longchuan Bai et al.   CANCER CELL

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

(2019) Haibin Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Direct Targeting Options for STAT3 and STAT5 in Cancer

(2019) Anna Orlova et al.   Cancers

Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease

(2018) J. Morgan Knight et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacologic inhibition of STAT5 in acute myeloid leukemia

(2018) Bettina Wingelhofer et al.   LEUKEMIA

STAT5 in Cancer and Immunity

(2016) Aradhana Rani et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Induced protein degradation: an emerging drug discovery paradigm

(2016) Ashton C. Lai et al.   NATURE REVIEWS DRUG DISCOVERY

An SH2 domain model of STAT5 in complex with phospho-peptides define “STAT5 Binding Signatures”

(2015) Eleonora Gianti et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity

(2015) Pijus K. Mandal et al.   JOURNAL OF MEDICINAL CHEMISTRY

Catalytic in vivo protein knockdown by small-molecule PROTACs

(2015) Daniel P Bondeson et al.   Nature Chemical Biology

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes

(2014) Graeme C. McAlister et al.   ANALYTICAL CHEMISTRY

JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia

(2013) W. Warsch et al.   BLOOD

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice

(2012) C. Walz et al.   BLOOD

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

(2012) Oliver Hantschel et al.   Nature Chemical Biology

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis

(2011) Gregor Hoermann et al.   AMERICAN JOURNAL OF PATHOLOGY

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Critical requirement for Stat5 in a mouse model of polycythemia vera

(2011) D. Yan et al.   BLOOD

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

(2011) Bo Li et al.   BMC BIOINFORMATICS

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia

(2010) Andrea Hoelbl et al.   EMBO Molecular Medicine

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation

(2009) G. Yoshimoto et al.   BLOOD